Status:

COMPLETED

MicroRNAs and Prognosis in Breast Cancer

Lead Sponsor:

Casa Sollievo della Sofferenza IRCCS

Conditions:

Breast Cancer Female

Metastases Breast

Eligibility:

FEMALE

18+ years

Brief Summary

Mono-centric, observational retrospective and prospective study, designed for breast cancer patients to identify novel miRNA based biomarker able to predict metastases development in breast cancer pat...

Detailed Description

The potential role of miRNAs will be studied as a predictor of metastases development. miRNAs expression and miRNAs promoter methylation will be evaluated in surgically removed specimens obtained from...

Eligibility Criteria

Inclusion

  • Retrospective Cohort
  • Tissue samples from breast cancer cases diagnosed from 2004 to 2014 for which informed consent for tumour banking and complete clinicopathological and follow up data were available.

Exclusion

  • Pre-surgery neoadjuvant treatment for breast cancer with chemotherapy, lapatinib, trastuzumab, letrozole, anastrozole, exemestane or tamoxifen.
  • Other cancers diagnosed in the last five years.
  • Prospective Cohort:
  • Inclusion Criteria:
  • Ability to provide written informed consent; Age greater than 18 years; Histological diagnosis of Breast disease; First diagnosis of Breast Cancer; Syncronous distant metastasis absent.

Key Trial Info

Start Date :

October 28 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 28 2019

Estimated Enrollment :

1432 Patients enrolled

Trial Details

Trial ID

NCT06555354

Start Date

October 28 2014

End Date

November 28 2019

Last Update

August 15 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Casa sollievo della Sofferenza IRCCS

San Giovanni Rotondo, FG, Italy, 71013

MicroRNAs and Prognosis in Breast Cancer | DecenTrialz